entity,start_date,end_date,context,AARSRAPPORT_html,AARSRAPPORT_pdf,AARSRAPPORT_xml,AddressOfAuditorDistrictName,AddressOfAuditorPostCodeIdentifier,AddressOfAuditorStreetBuildingIdentifier,AddressOfAuditorStreetName,AddressOfFinancialDistrictName,AddressOfFinancialPostCodeIdentifier,AddressOfFinancialStreetBuildingIdentifier,AddressOfFinancialStreetName,AddressOfLawFirmDistrictName,AddressOfLawFirmPostCodeIdentifier,AddressOfLawFirmStreetBuildingIdentifier,AddressOfLawFirmStreetName,AddressOfReportingEntityDistrictName,AddressOfReportingEntityPostCodeIdentifier,AddressOfReportingEntityStreetBuildingIdentifier,AddressOfReportingEntityStreetName,AddressOfSubmittingEnterprisePostcodeAndTown,AddressOfSubmittingEnterpriseStreetAndNumber,AddresseeOfAuditorsReportOnAuditedFinancialStatements,AdministrativeExpenses,ClassOfReportingEntity,ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement,ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults,CostOfSales,DateOfApprovalOfAnnualReport,DateOfGeneralMeeting,DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies,DescriptionOfMethodsOfCurrentTaxReceivablesAndLiabilities,DescriptionOfMethodsOfForeignCurrencies,DescriptionOfMethodsOfPrepayments,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeLiabilities,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDistributionCosts,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInventories,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfProvisions,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax,DescriptionOfMethodsOfStatingKeyFiguresAndFinancialRatiosIncludedInManagementReview,DescriptionOfMethodsOfTranslationOfForeignCurrencies,DescriptionOfQualificationsOfAuditedFinancialStatements,DisclosureOfContingentLiabilities,DisclosureOfContributedCapital,DisclosureOfEmployeeBenefitsExpense,DisclosureOfOtherFinanceExpenses,DisclosureOfOtherFinanceIncome,DisclosureOfOtherProvisions,DisclosureOfOwnership,DisclosureOfPropertyPlantAndEquipment,DisclosureOfTaxExpenses,DistributionCosts,ExplanationOfNotDisclosingCashFlowsStatements,GrossResult,IdentificationNumberCvrOfAuditFirm,IdentificationNumberCvrOfReportingEntity,IdentificationNumberCvrOfSubmittingEnterprise,IdentificationOfApprovedAnnualReport,IndependentAuditorsReportsAudit,InformationOnCalculationOfKeyFiguresAndFinancialRatios,InformationOnCurrentDeferredTaxAssets,InformationOnRelatedEntities,InformationOnReportingClassOfEntity,InformationOnSegments,InformationOnTypeOfSubmittedReport,ManagementsReview,ManagementsStatementAboutManagementsReview,NameAndSurnameOfChairmanOfGeneralMeeting,NameAndSurnameOfMemberOfExecutiveBoard,NameOfAuditFirm,NameOfFinancialInstitution,NameOfLawFirm,NameOfReportingEntity,NameOfSubmittingEnterprise,OpinionOnAuditedFinancialStatements,OtherFinanceExpenses,OtherFinanceIncome,PlaceOfSignatureOfStatement,PrecedingReportingPeriodStartDate,PredingReportingPeriodEndDate,ProfitLoss,ProfitLossFromOrdinaryActivitiesBeforeTax,ProfitLossFromOrdinaryOperatingActivities,RecommendationForApprovalOfAnnualReportByGeneralMeeting,RegisteredOfficeOfReportingEntity,ReportingPeriodEndDate,ReportingPeriodStartDate,Revenue,SignatureOfAuditorsDate,SignatureOfAuditorsPlace,StatementByExecutiveAndSupervisoryBoards,StatementOfAuditorsResponsibilityForAuditAndAuditPerformed,StatementOfChangesInEquity,StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements,TaxExpense,TitleOfMemberOfSupervisoryBoard,TypeOfAuditorAssistance,_id,_index,_score,cvrNummer,indlaesningsId,indlaesningsTidspunkt,offentliggoerelsesTidspunkt,offentliggoerelsestype,omgoerelse,regNummer,regnskabsperiode_slutDato,regnskabsperiode_startDato,sagsNummer,sidstOpdateret,Assets,CashAndCashEquivalents,ContributedCapital,CurrentAssets,DepositsLongtermInvestmentsAndReceivables,Equity,FixturesFittingsToolsAndEquipment,Inventories,LeaseholdImprovements,LiabilitiesAndEquity,LiabilitiesOtherThanProvisions,LongtermInvestmentsAndReceivables,NoncurrentAssets,OtherProvisions,OtherShorttermPayables,OtherShorttermReceivables,PropertyPlantAndEquipment,ProposedDividendRecognisedInEquity,Provisions,ProvisionsForDeferredTax,RetainedEarnings,ShorttermDeferredIncome,ShorttermLiabilitiesOtherThanProvisions,ShorttermPayablesToGroupEnterprises,ShorttermReceivables,ShorttermReceivablesFromGroupEnterprises,ShorttermTaxPayables,ShorttermTaxReceivables,ShorttermTradePayables,ShorttermTradeReceivables,AverageNumberOfEmployees,GrossMargin,ResultsFromNetFinancials,ReturnOnCapitalEmployed,ReturnOnEquity,SolvencyRatio,NameOfKeyFigureOrFinancialRatio,ValueOfKeyFigureOrFinancialRatioMonetary,DescriptionOfAuditor,NameAndSurnameOfAuditor,ValueOfKeyFigureOrFinancialRatio,NameAndSurnameOfMemberOfSupervisoryBoard
29476012,2015-10-01,2016-09-30,ctx27,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",3694170.0,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",190173794.0,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",13607166.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",42095619.0,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",2392142.0,3737494.0,Herlev,2015-10-01,2016-09-30,19929631.0,26139635.0,24794283.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,232269413.0,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",6210004.0,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2015-10-01,2016-09-30,ctx29,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,68081086.0,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2015-10-01,2016-09-30,ctx31,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,-20000000.0,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2016-09-30,2016-09-30,ctx32,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,200978433.0,95862784.0,750000.0,199600537.0,316251.0,68831086.0,678624.0,13673855.0,383021.0,200978433.0,124061629.0,316251.0,1377896.0,8026768.0,23494535.0,64401488.0,1061645.0,20000000.0,8085718.0,58950.0,48081086.0,17401478.0,124061629.0,76905888.0,90063898.0,11290628.0,5758718.0,0.0,501010.0,14371782.0,,,,,,,,,,,,
29476012,2016-10-01,2017-09-30,ctx1,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",4323423.0,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",124774490.0,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",12466470.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",29674438.0,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",6498082.0,1241136.0,Herlev,2015-10-01,2016-09-30,6318258.0,7627599.0,12884545.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,154448928.0,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",1309341.0,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45.0,0.192,5257000.0,0.046,0.102,0.198,,,,,,
29476012,2016-10-01,2017-09-30,ctx10,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",45729000.0,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,19813000.0,,2617000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,227997000.0,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37.0,0.201,139000.0,0.142,0.406,0.304,,,,,,
29476012,2016-10-01,2017-09-30,ctx11,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",45049000.0,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,18101000.0,,26135000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,215153000.0,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,36.0,0.209,2073000.0,0.183,0.396,0.294,,,,,,
29476012,2016-10-01,2017-09-30,ctx12,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Investment in fixed assets,745000.0,,,,
29476012,2016-10-01,2017-09-30,ctx13,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Investment in fixed assets,131000.0,,,,
29476012,2016-10-01,2017-09-30,ctx14,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Investment in fixed assets,689000.0,,,,
29476012,2016-10-01,2017-09-30,ctx15,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Investment in fixed assets,1375000.0,,,,
29476012,2016-10-01,2017-09-30,ctx16,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Investment in fixed assets,577000.0,,,,
29476012,2016-10-01,2017-09-30,ctx2,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,State Authorised Public Accountant,Jesper Wiinholt,,
29476012,2016-10-01,2017-09-30,ctx22,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin,,,,83.0,
29476012,2016-10-01,2017-09-30,ctx23,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin,,,,107.0,
29476012,2016-10-01,2017-09-30,ctx24,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin,,,,98.0,
29476012,2016-10-01,2017-09-30,ctx25,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin,,,,115.0,
29476012,2016-10-01,2017-09-30,ctx26,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Profit margin,,,,121.0,
29476012,2016-10-01,2017-09-30,ctx28,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,54399344.0,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2016-10-01,2017-09-30,ctx3,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2016-10-01,2017-09-30,ctx30,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,-20000000.0,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2016-10-01,2017-09-30,ctx4,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Michael Sandhu
29476012,2016-10-01,2017-09-30,ctx5,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,JÃ¸rgen Kjergaard Madsen
29476012,2016-10-01,2017-09-30,ctx6,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Vagn Thorup
29476012,2016-10-01,2017-09-30,ctx7,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,State Authorised Public Accountant,Ferass Hamade,,
29476012,2016-10-01,2017-09-30,ctx8,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",42096000.0,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,1993000.0,,24794000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,232269000.0,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37.0,0.181,1345000.0,0.123,0.317,0.342,,,,,,
29476012,2016-10-01,2017-09-30,ctx9,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",42434000.0,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,2114000.0,,22395000.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,229294000.0,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,38.0,0.185,5254000.0,0.082,0.375,0.209,,,,,,
29476012,2017-09-30,2017-09-30,ctx17,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,278704783.0,79022448.0,750000.0,277250225.0,324157.0,55149344.0,962599.0,26772024.0,167802.0,278704783.0,218361796.0,324157.0,1454558.0,5152410.0,22540829.0,69025136.0,1130401.0,20000000.0,5193643.0,41233.0,34399344.0,32407060.0,218361796.0,161569126.0,171455753.0,9846851.0,0.0,1330812.0,1844781.0,91252954.0,,,,,,,,,,,,
29476012,2017-09-30,2017-09-30,ctx18,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,200978000.0,,,,,68831000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2017-09-30,2017-09-30,ctx19,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,27176000.0,,,,,56901000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2017-09-30,2017-09-30,ctx20,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,183721000.0,,,,,55761000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
29476012,2017-09-30,2017-09-30,ctx21,,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzFiLzgwL2RiL2VkLzYwY2YtNDBhMy05ZDczLWJkYzI3ZDhkMzRlNw.pdf,http://regnskaber.virk.dk/21067492/ZG9rdW1lbnRsYWdlcjovLzAzLzE2LzViLzY3L2EyLzc2MTItNGQ3YS1iY2Q5LTNlNjUxYWMzZTcwZQ.xml,Hellerup,DK-2900,44.0,Strandvejen,KÃ¸benhavn K,DK-1092,2 - 12,Holmens Kanal,KÃ¸benhavn Ã,DK-2100,5.0,Sundkrogsgade,Herlev,2730.0,9.0,LyskÃ¦r,2900 Hellerup,Strandvejen 44,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">To the Shareholders of Varian Medical Systems Scandinavia A/S</td></tr></table>",,"Regnskabsklasse C, mellemstor virksomhed","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report is prepared in accordance with the Danish Financial Statements Act.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, the Annual Report give a true and fair view of the financial position at 30 September 2017 of the Company operations for 2016/2017.</td></tr></table>",,2017-12-12,2017-12-12,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Recognition and measurement</td></tr><tr><td colspan=""1"">The financial statements have been prepared under the historical cost method.</td></tr><tr><td colspan=""1"">Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised costs are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.</td></tr><tr><td colspan=""1"">Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.</td></tr><tr><td colspan=""1"">Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.</td></tr><tr><td colspan=""1"">Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.</td></tr><tr><td colspan=""1"">Certain financial assets and liabilities are measured at amortised cost, which involves the recognition of a constant effective interest rate over the maturity period. Amortised cost is calculated as original cost less any repayments and with addition/deduction of the cumulative amortisation of any difference between cost and the nominal amount. In this way, capital losses and gains are allocated over the maturity period.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Current tax receivables are recognised in receivables in the balance sheet in the event of overpayment, while current tax liabilities are recognised in short-term debt in the event of non-payment.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Accounts in foreign currencies</td></tr><tr><td colspan=""1"">Assets and liabilities in foreign currencies are translated into Danish kroner at the official rates of exchange on the balance sheet date.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Prepayments</td></tr><tr><td colspan=""1"">Prepayments recognised in assets include expenses incurred in respect of subsequent financial years, typically prepaid rent, insurance premiums, subscriptions, etc. as well as fair value adjustments of derivative financial instruments with a positive fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Administrative and sundry indirect expenses</td></tr><tr><td colspan=""1"">Administrative and sundry indirect expenses comprise salaries, stationery and other external expenses.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cost of sales</td></tr><tr><td colspan=""1"">As in previous years, cost of sales consists of cost prices of the equipment delivered plus customs and costs of transportation to the place of business as well as expenses for installations and guarantee services. Direct delivery charges and expenses for training of customers in the application of the equipment are also included in cost of sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred income and other debt</td></tr><tr><td colspan=""1"">Deferred income recognised as debt comprises payments received concerning income in subsequent years and fair value adjustments of derivative financial instruments with a negative fair value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Sales and marketing expenses</td></tr><tr><td colspan=""1"">Sales and marketing expenses comprise the salary, staff, travelling and external expenses directly related to the sales and marketing activity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Equity</td></tr><tr><td colspan=""1"">Dividend</td></tr><tr><td colspan=""1"">Dividend is recognised as a liability at the time of adoption at the Annual General Meeting. Dividend expected to be distributed for the year is disclosed as a separate equity item.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial income and expenses</td></tr><tr><td colspan=""1"">Financial income and expenses comprise interest and realized and unrealized exchange rate adjustments.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Inventories</td></tr><tr><td colspan=""1"">Inventories are measured under the FIFO principle at cost with addition of costs of transportation to the place of business. Considering the date of acquisition, write-down has been made to meet losses due to technical obsolescence.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial debts</td></tr><tr><td colspan=""1"">Debts are measured at amortised cost, substantially corresponding to nominal value.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Property, plant and equipment</td></tr><tr><td colspan=""1"">Property, plant and equipment are measured at cost less any accumulated depreciation. Depreciation is made on a straight line basis as follows</td></tr><tr><td colspan=""1"">Fixtures, fittings, tools and equipment 3-5 years</td></tr><tr><td colspan=""1"">Leasehold improvements 5 years</td></tr><tr><td colspan=""1"">Motor Vehicles 5 years</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Provisions</td></tr><tr><td colspan=""1"">Provisions are recognised when - in consequence of an event occurred before or on the balance sheet date - the Company has a legal or constructive obligation and it is probable that economic benefits must be given up to settle the obligation.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Receivables</td></tr><tr><td colspan=""1"">Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value, which corresponds to nominal value less provisions for bad debts. Provisions for bad debts are determined on the basis of an individual assessment of each receivable, and in respect of trade receivables, a general provision is also made.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Revenue</td></tr><tr><td colspan=""1"">Revenue is recognised in the income statement when the sale is considered effected based on the following criteria</td></tr><tr><td colspan=""1"">- delivery has been made before year end;</td></tr><tr><td colspan=""1"">- a binding sales agreement has been made;</td></tr><tr><td colspan=""1"">- the sales price has been determined and</td></tr><tr><td colspan=""1"">- payment has been received or may with reasonable certainty be expected to be received.</td></tr><tr><td colspan=""1"">Revenue collected on behalf of a principal is not recognised as revenue. Instead the commission which the company receives from the principal is recognised and there is no gross presentation of the full selling price and the related costs of sales.</td></tr><tr><td colspan=""1"">Revenue is recognised exclusive of VAT and net of discounts relating to sales.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Corporation tax and deferred tax</td></tr><tr><td colspan=""1"">Tax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity entries is recognised directly in equity. Any share of the tax reported in the income statement arising from profit/loss on extraordinary activities for the year is attributed to such activities, whereas the remaining share is attributed to profit/loss on ordinary activities for the year.</td></tr><tr><td colspan=""1"">Current tax is calculated at the tax rate applying for the year.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax is recognised in the balance sheet as the tax on all temporary differences. Deferred tax is calculated at the tax rate which, based on legislation passed before the end of the financial year, will apply at the time when it is expected to be realised.</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Deferred tax assets are recognised at the value at which they are expected to be realised.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Financial ratios</td></tr><tr><td colspan=""1"">The financial ratios have been calculated in accordance with the guidelines issued by the Danish Society of Financial Analysts.</td></tr><tr><td colspan=""1"">The financial ratios have been calculated as follows</td></tr><tr><td colspan=""1"">Gross margin = (Gross profit x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Profit margin = (Profit before financials x 100)/(Revenue)</td></tr><tr><td colspan=""1"">Return on net assets = (Profit before financials x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Solvency ratio = (Equity at year - end x 100)/(Total assets)</td></tr><tr><td colspan=""1"">Return on equity = (Net profit for the year x 100)/((Equity at year - end + Equity at year start)/2)</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Translation policies</td></tr><tr><td colspan=""1"">Transactions in foreign currencies are translated at the exchange rates at the dates of transaction. Gains and losses arising due to differences between the transaction date rates and the rates at the dates of payment are recognized in financial income and expenses in the income statement. Where foreign exchange transactions are considered hedging of future cash flows, the value adjustments are recognized directly in equity.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Basis for Opinion</td></tr><tr><td colspan=""1"">We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Contingent liabilities and security</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has undertaken lease obligations which run until 2021.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The total lease obligations amount to kDKK 2.680 of which kDKK 1.520 falls due within 1 year and kDKK 1.160 falls due within 1 - 5 years.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company has issued third party guarantees of kDKK 140.095</td></tr><tr><td colspan=""1""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >Share capital</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The share capital consists of 75 shares of a nominal amount of DKK 10,000 or multiples hereof.</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >No shares carry any special rights.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Staff expenses</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >2016/2017</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td></tr><tr><td width=""79%"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Wages and salaries</td><td width=""10%"" align=""right"" valign=""middle"" >37.255.399</td><td width=""11%"" align=""right"" valign=""middle"" >33.104.303</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other expenses for social security and pensions</td><td width=""10%"" align=""right"" valign=""middle"" >3.978.668</td><td width=""11%"" align=""right"" valign=""middle"" >3.348.744</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >41.234.067</td><td width=""11%"" align=""right"" valign=""middle"" >36.453.047</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The amount is distributed on the items ""Cost of Sales"", ""Sales and marketing expenses"" and Administation and sundry indirect expenses in the Income Statement.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >In pursuance of section 98b(3) of the Danish Financial Statements Act, the remuneration to the Executive Board is not stated.</td></tr><tr><td colspan=""3""></td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Directors' fees of DKK 120,000 have been paid.</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Average number of employees</td><td width=""10%"" align=""right"" valign=""middle"" >45</td><td width=""11%"" align=""right"" valign=""middle"" >37</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial expenses</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest expenses</td><td width=""10%"" align=""right"" valign=""middle"" >7.193</td><td width=""11%"" align=""right"" valign=""middle"" >407</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange losses</td><td width=""10%"" align=""right"" valign=""middle"" >6.490.889</td><td width=""11%"" align=""right"" valign=""middle"" >2.391.735</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >6.498.082</td><td width=""11%"" align=""right"" valign=""middle"" >2.392.142</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Financial income</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Interest income</td><td width=""10%"" align=""right"" valign=""middle"" >399.621</td><td width=""11%"" align=""right"" valign=""middle"" >30.587</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Exchange gains</td><td width=""10%"" align=""right"" valign=""middle"" >841.515</td><td width=""11%"" align=""right"" valign=""middle"" >3.706.907</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.241.136</td><td width=""11%"" align=""right"" valign=""middle"" >3.737.494</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Other provisions</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Warranty obligations</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Other provisions at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >5.152.410</td><td width=""11%"" align=""right"" valign=""middle"" >8.026.768</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The warranty obligations are guarantees granted in connection with sales of systems.</td></tr><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >The guarantees typically run for 12 months after delivery.</td></tr><tr><td colspan=""3""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Group</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Company's ultimate Parent Company, which prepares Consolidated Financial Statements in which the Company is included as a subsidiary, is Varian Medical Systems Inc., Palo Alto,</td></tr><tr><td width=""100%"" colspan=""1"" align=""left"" valign=""middle"" >The Annual Report of the Parent Company can be obtained at the Company's address.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Property, plant and equipment</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Fixtures, fittings, tools and equipment</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >Motor vehicles</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >Leasehold improvements</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >4.307.590</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.235.835</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Additions during the year</td><td width=""8%"" align=""right"" valign=""middle"" >745.096</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >745.096</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Disposals during the year</td><td width=""8%"" align=""right"" valign=""middle"" >-544.291</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-557.711</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >4.508.395</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >914.825</td><td width=""11%"" align=""right"" valign=""middle"" >5.423.220</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 1 October</td><td width=""8%"" align=""right"" valign=""middle"" >3.628.966</td><td width=""8%"" align=""right"" valign=""middle"" >13.420</td><td width=""7%"" align=""right"" valign=""middle"" >531.804</td><td width=""11%"" align=""right"" valign=""middle"" >4.174.190</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation</td><td width=""8%"" align=""right"" valign=""middle"" >424.841</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >215.219</td><td width=""11%"" align=""right"" valign=""middle"" >640.060</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Reversal of depreciation of disposals for the year</td><td width=""8%"" align=""right"" valign=""middle"" >-508.011</td><td width=""8%"" align=""right"" valign=""middle"" >-13.420</td><td width=""7%"" align=""right"" valign=""middle"" >0</td><td width=""11%"" align=""right"" valign=""middle"" >-521.431</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciation and impairment at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >3.545.796</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >747.023</td><td width=""11%"" align=""right"" valign=""middle"" >4.292.819</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Carrying amount at 30 September</td><td width=""8%"" align=""right"" valign=""middle"" >962.599</td><td width=""8%"" align=""right"" valign=""middle"" >0</td><td width=""7%"" align=""right"" valign=""middle"" >167.802</td><td width=""11%"" align=""right"" valign=""middle"" >1.130.401</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Depreciated over</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3 - 5 Ã¥r</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 Ã¥r</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >3-5 years</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" >5 years</td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""left"" valign=""middle"" >2016/2017</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >2015/2016</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""8%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""7%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""11%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td colspan=""5""></td></tr><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >The depreciation for the year is distributed on the following items in the Income Statement</td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Cost of sales</td><td width=""8%"" align=""right"" valign=""middle"" >591.771</td><td width=""8%"" align=""right"" valign=""middle"" >643.095</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Sales and marketing expenses</td><td width=""8%"" align=""right"" valign=""middle"" >20.853</td><td width=""8%"" align=""right"" valign=""middle"" >45.511</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" colspan=""1"" align=""left"" valign=""middle"" >Administration and sundry indirect expenses</td><td width=""8%"" align=""right"" valign=""middle"" >27.436</td><td width=""8%"" align=""right"" valign=""middle"" >37.665</td><td width=""7%"" ></td><td width=""11%"" ></td></tr><tr><td width=""66%"" ></td><td width=""8%"" align=""right"" valign=""middle"" >640.060</td><td width=""8%"" align=""right"" valign=""middle"" >726.271</td><td width=""7%"" ></td><td width=""11%"" ></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Tax for the year</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment, previous years</td><td width=""10%"" align=""right"" valign=""middle"" >-394.486</td><td width=""11%"" align=""right"" valign=""middle"" >15.901</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Calculated corporation tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >1.721.544</td><td width=""11%"" align=""right"" valign=""middle"" >6.577.486</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Adjustment of deferred tax</td><td width=""10%"" align=""right"" valign=""middle"" >-17.717</td><td width=""11%"" align=""right"" valign=""middle"" >-383.383</td></tr><tr><td width=""79%"" ></td><td width=""10%"" align=""right"" valign=""middle"" >1.309.341</td><td width=""11%"" align=""right"" valign=""middle"" >6.210.004</td></tr><tr><td colspan=""3""></td></tr></table>",,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Cash Flow Statement</td></tr><tr><td colspan=""1"">In pursuance of section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared as the cash flow statement is included in the Consolidated Financial Statements of the Companyâs Parent Company.</td></tr></table>",,33771231.0,29476012.0,33771231.0,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Executive and Supervisory Boards have today considered and adopted the Annual Report of Varian Medical Systems Scandinavia AS for the financial year 2016/2017.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Independent Auditorâs Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Seen over a five-year period the development of the Company is described by the following financial highlights</td></tr></table><br><table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">For definitions see under accounting policies.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""3"" align=""left"" valign=""middle"" >Deferred tax assets</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 1 October</td><td width=""10%"" align=""right"" valign=""middle"" >-58.950</td><td width=""11%"" align=""right"" valign=""middle"" >-442.333</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax for the year</td><td width=""10%"" align=""right"" valign=""middle"" >17.717</td><td width=""11%"" align=""right"" valign=""middle"" >383.383</td></tr><tr><td width=""79%"" colspan=""1"" align=""left"" valign=""middle"" >Deferred tax at 30 September</td><td width=""10%"" align=""right"" valign=""middle"" >-41.233</td><td width=""11%"" align=""right"" valign=""middle"" >-58.950</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Related parties and ownership</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Controlling interest</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Basis</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >Varian Medical Systems International Holdings Inc.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Parent Company</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" ></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Palo Alto, Californien, USA</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Significant influence</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The Executive and Supervisory Boards exercise significant influence by their managerial duties in the Company.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Transactions</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >As part of the ordinary operation of the Company, trade has been effected with related enterprises and shareholders with significant influence. The trade has been effected on an arm's length basis.</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Apart from the below transactions in the financial year within the group, there have been no transactions with the Supervisory Board, the Executive Board, senior employees, significant shareholders, group enterprises or other related parties, except for normal management remuneration and fee for legal advisory services.</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >Country</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Purchase</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >Sale</td></tr><tr><td width=""72%"" ></td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >DKK '000</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td><td width=""10%"" colspan=""1"" align=""right"" valign=""middle"" >DKK '000</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS, Inc.</td><td width=""9%"" colspan=""1"" align=""left"" valign=""middle"" >USA</td><td width=""9%"" align=""right"" valign=""middle"" >52.876</td><td width=""10%"" align=""right"" valign=""middle"" >1.174</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS UK Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >UK</td><td width=""9%"" align=""right"" valign=""middle"" >2.553</td><td width=""10%"" align=""right"" valign=""middle"" >1.510</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS International A.G.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Switzerland</td><td width=""9%"" align=""right"" valign=""middle"" >31.717</td><td width=""10%"" align=""right"" valign=""middle"" >6.737</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Nederland B.V.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >The Netherlands</td><td width=""9%"" align=""right"" valign=""middle"" >163</td><td width=""10%"" align=""right"" valign=""middle"" >52</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Belgium NV</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Belgium</td><td width=""9%"" align=""right"" valign=""middle"" >1.075</td><td width=""10%"" align=""right"" valign=""middle"" >164</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS GesmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >800</td><td width=""10%"" align=""right"" valign=""middle"" >601</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Finland OY</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Ãstrig/Austria</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >60</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Deutchland GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Finland</td><td width=""9%"" align=""right"" valign=""middle"" >121</td><td width=""10%"" align=""right"" valign=""middle"" >1.368</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS India Pvt. Ltd.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >India</td><td width=""9%"" align=""right"" valign=""middle"" >78</td><td width=""10%"" align=""right"" valign=""middle"" >196</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica S.L.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Spain</td><td width=""9%"" align=""right"" valign=""middle"" >104</td><td width=""10%"" align=""right"" valign=""middle"" >16</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Iberica Surcursal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Portugal</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >40</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Haan GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Tyskland/Germa</td><td width=""9%"" align=""right"" valign=""middle"" >714</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Particle Therapy GmbH</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Germany</td><td width=""9%"" align=""right"" valign=""middle"" >55.650</td><td width=""10%"" align=""right"" valign=""middle"" >8.668</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS France</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >France</td><td width=""9%"" align=""right"" valign=""middle"" >463</td><td width=""10%"" align=""right"" valign=""middle"" >53</td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Italia, S.p.A.</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Italy</td><td width=""9%"" align=""right"" valign=""middle"" >44</td><td width=""10%"" ></td></tr><tr><td width=""72%"" colspan=""1"" align=""left"" valign=""middle"" >VMS Arabia LLC</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" >Saudi Arabia</td><td width=""9%"" colspan=""1"" align=""right"" valign=""middle"" ></td><td width=""10%"" align=""right"" valign=""middle"" >23</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >VMS is used as abriviation for Varian Medical Systems.</td></tr><tr><td colspan=""4""></td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Ownership</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >The following shareholders are recorded in the Company's register of shareholders as holding at least 5% of the votes or at least 5% of the share capital</td></tr><tr><td width=""100%"" colspan=""4"" align=""left"" valign=""middle"" >Varian Medical Systems Nederland B.V., Houten, Holland</td></tr><tr><td colspan=""4""></td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">The Annual Report of Varian Medical Systems Scandinavia AS for the financial year 1 October 2016 â 30 September 2017 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to medium-sized enterprises of reporting class C.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Segment reporting</td></tr><tr><td colspan=""1"">For competitive reasons the Company has chosen not to specify information on segments.</td></tr></table>",Ãrsrapport,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Review</td></tr><tr><td colspan=""1"">Main activity</td></tr><tr><td colspan=""1"">The Companyâs activities consist of sale and service of oncology systems within Scandinavia and Iceland. The business is run from rented premised at Herlev. The company has a permanent establishment in Sweden.</td></tr><tr><td colspan=""1"">Development in the year</td></tr><tr><td colspan=""1"">The Companyâs result and financial development exceeded expectations and is considered satisfactory. The result for the year was a profit of DKK 6,318,258 against DKK 19,929,631 in 2015/2016. The company has established an office at the Danish Centre for Particle Therapy in Aarhus.</td></tr><tr><td colspan=""1"">Post-balance sheet events</td></tr><tr><td colspan=""1"">After the balance sheet date, no significant events have occurred which are considered to have a material influence on the assessment of the Annual Report.</td></tr><tr><td colspan=""1"">The expected development</td></tr><tr><td colspan=""1"">It is assumed that revenue and results for the financial year 2017/2018 will end higher than reported for the financial year 2016/2017.</td></tr><tr><td colspan=""1"">Financial risks</td></tr><tr><td colspan=""1"">Credit facility etc. up to DKK 209 million at Danske Bank is guaranteed by the Companyâs Parent Company.</td></tr><tr><td colspan=""1"">Special risks</td></tr><tr><td colspan=""1"">Revenue and thereby results are affected by political grants as the Companyâs customers are mainly public hospitals. Moreover, the exchange rate development between the Nordic currencies and the USD is of importance to the results. The Company does not hedge the currency positions.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review</td></tr></table>",JÃ¸rgen Kjergaard Madsen,Sten Hornsleth,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,Danske Bank,KromanReumert,Varian Medical Systems Scandinavia A/S,PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Opinion</td></tr><tr><td colspan=""1"">In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 30 September 2017, and of the results of the Companyâs operations for the financial year 1 October 2016 - 30 September 2017 in accordance with the Danish Financial Statements Act.</td></tr><tr><td colspan=""1"">We have audited the Financial Statements of Varian Medical Systems Scandinavia A/S for the financial year 1 October 2016 - 30 September 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</td></tr></table>",,,Herlev,2015-10-01,2016-09-30,,,,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">We recommend that the Annual Report be adopted at the Annual General Meeting.</td></tr></table>",Herlev,2017-09-30,2016-10-01,,2017-12-12,Hellerup,"<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Statement on the Annual Report</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Auditorâs Responsibilities for the Audit of the Financial Statements</td></tr><tr><td colspan=""1"">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.</td></tr><tr><td colspan=""1"">As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also</td></tr><tr><td colspan=""1"">-  Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.</td></tr><tr><td colspan=""1"">-  Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.</td></tr><tr><td colspan=""1"">-  Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan=""1"">-  Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.</td></tr><tr><td colspan=""1"">-  Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan=""1"">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td width=""100%"" colspan=""5"" align=""left"" valign=""middle"" >Statement of Changes in Equity</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >Share capital</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >Ratained earnings</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >Proposed dividend for the year</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >Total</td></tr><tr><td width=""11%"" ></td><td width=""15%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""21%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""36%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td><td width=""17%"" colspan=""1"" align=""right"" valign=""middle"" >DKK</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Adjusted equity at 1 October</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >48.081.086</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >68.831.086</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Dividends distributed</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >0</td><td width=""36%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >-20.000.000</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Net profit for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >6.318.258</td><td width=""36%"" align=""right"" valign=""middle"" >0</td><td width=""17%"" align=""right"" valign=""middle"" >6.318.258</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Proposed dividend for the year</td><td width=""15%"" align=""right"" valign=""middle"" >0</td><td width=""21%"" align=""right"" valign=""middle"" >-20.000.000</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >0</td></tr><tr><td width=""11%"" colspan=""1"" align=""left"" valign=""middle"" >Equity at 30 September</td><td width=""15%"" align=""right"" valign=""middle"" >750.000</td><td width=""21%"" align=""right"" valign=""middle"" >34.399.344</td><td width=""36%"" align=""right"" valign=""middle"" >20.000.000</td><td width=""17%"" align=""right"" valign=""middle"" >55.149.344</td></tr></table>","<table xmlns=""http://www.w3.org/1999/xhtml"" style=""border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse""  width=""100%""><tr><td colspan=""1"">Managementâs Responsibilities for the Financial Statements</td></tr><tr><td colspan=""1"">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan=""1"">In preparing the financial statements, Management is responsible for assessing the Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table>",,Chairman,RevisionspÃ¥tegning,urn:ofk:oid:24912480,indberetninger-20180424,2.5095882,29476012.0,,2018-04-03T13:47:27.042Z,2018-01-03T20:34:53.796Z,regnskab,0.0,,2017-09-30,2016-10-01,X18-AA-23-WH,2018-01-03T20:34:54.023Z,142524000.0,,,,,41949000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
